Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pirfenidone inhalation - Avalyn Pharmaceuticals

Next Previous
Search
Drug Profile

Pirfenidone inhalation - Avalyn Pharmaceuticals

Alternative Names: Aerodone; AP 01; GP 101

Latest Information Update: 07 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avalyn Pharma
  • Class Anti-inflammatories; Antifibrotics; Heart failure therapies; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Interstitial lung diseases; Pulmonary fibrosis

Most Recent Events

  • 30 Apr 2025 Avalyn Pharma plans to initiate a phase II trial for Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis (Treatment experienced) in Australia (Inhalation) (NCT06951217)
  • 19 Nov 2024 Phase-II clinical trials in Pulmonary fibrosis (Treatment-experienced) in Australia, Canada, France, Italy, Germany, New Zealand, Poland, Spin, and, United Kingdom (Inhalation) (NCT06329401)
  • 07 Sep 2024 Adverse event and pharmacodynamics data from the phase I/II ATLAS trial in Idiopathic pulmonary fibrosis presented at the 34th Annual Congress of the European Respiratory Society 2024 (ERS-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top